Fortrea Holdings Inc.
FTRENasdaqHealthcare · Services-Medical Laboratories · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $2.72B | $2.70B | $2.84B | $2.84B | $3.06B |
| Operating income | −$872.6M | −$161.9M | $32.0M | $187.1M | $114.3M |
| Net income | −$986.2M | −$328.5M | −$25.2M | $186.2M | $98.0M |
| Total assets | $2.72B | $3.58B | $4.33B | $4.29B | — |
| Total liabilities | $2.15B | $2.22B | $2.62B | $945.3M | — |
| Equity | $563.5M | $1.36B | $1.71B | $3.34B | $3.26B |
| EPS (diluted) | $-10.81 | $-3.67 | $-0.29 | $2.09 | $1.10 |
| Shares out. | 90.2M | 89.4M | 88.8M | 0 | 88.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −32.0%
- Net margin
- −36.2%
- Return on equity
- −175.0%
- Return on assets
- −36.3%
- Return on capital (ROCE)
- −48.4%
- Liabilities / assets
- 79.3%
- Debt / equity
- 3.82×
- Book value / share
- $6.25
- Revenue growth (YoY)
- 1.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -3.58distress
- Accruals / assets
- −40.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Sessa Capital (Master), L.P.Passive (13G)Feb 17, 2026
- Aqr Capital Management LlcPassive (13G)Nov 14, 2025
- Goldman Sachs Group IncPassive (13G)Aug 13, 2025
- Fmr LlcPassive (13G)Aug 6, 2025
- Morgan StanleyPassive (13G)Aug 5, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Blackrock Portfolio Management LlcPassive (13G)Jul 15, 2025
- Beck Mack & Oliver LlcPassive (13G)May 15, 2025
- Starboard Value LpActivist (13D)May 12, 2025
- Pacer Advisors, Inc.Passive (13G)May 2, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.5M | 5.5 | -10.1% |
| Apr 30, 2026 | 10.6M | 7.4 | -0.2% |
| Apr 15, 2026 | 10.6M | 11.9 | +2.6% |
| Mar 31, 2026 | 10.3M | 8.1 | -4.3% |
| Mar 13, 2026 | 10.8M | 5.9 | +13.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Results of operationsFeb 26, 2026
- Regulation FD disclosureNov 20, 2025
- Results of operationsNov 5, 2025
- Director / officer change · Regulation FD disclosureSep 22, 2025
- Director / officer changeAug 27, 2025
- Results of operationsAug 6, 2025
- Director / officer change · Shareholder voteJun 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4PRIMARY DOCUMENTMay 20, 2026
- 4PRIMARY DOCUMENTMay 18, 2026
- 144May 18, 2026
- 10-QMay 5, 2026
- 8-KMay 5, 2026
- SCHEDULE 13GApr 29, 2026
- ARSApr 27, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- SCHEDULE 13G/AMar 26, 2026
- 4PRIMARY DOCUMENTMar 24, 2026
- 4PRIMARY DOCUMENTMar 17, 2026
- 4PRIMARY DOCUMENTMar 17, 2026
- 144Mar 16, 2026
- 144Mar 16, 2026
Corporate family
Spun off from LabcorpLH · Jun 30, 2023
From the spin-off filings we track. Follow a company to walk its own history.